Intra-Cellular Therapies Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	24.63	14.24	11.42	8.98	8.03	Upgrade
Depreciation & Amortization	1.11	1.3	1.57	1.51	1.93	Upgrade
Loss (Gain) From Sale of Investments	-	-1.27	-	0.01	-0.09	Upgrade
Asset Writedown & Restructuring Costs	2.57	-	-	-	-	Upgrade
Change in Other Net Operating Assets	-61.35	-32.92	-1.85	-9.65	-2.05	Upgrade
Other Operating Activities	6.79	3.37	3.45	1.59	3.24	Upgrade
Operating Cash Flow	-6.51	-15.28	14.6	2.44	11.08	Upgrade
Operating Cash Flow Growth	-	-	498.56%	-77.98%	-40.71%	Upgrade
Capital Expenditures	-	-0.61	-0.08	-1.43	-	Upgrade
Sale of Property, Plant & Equipment	2.74	-	-	-	-	Upgrade
Other Investing Activities	-	0.01	-	-	-	Upgrade
Investing Cash Flow	2.74	-0.6	-0.08	-1.43	-	Upgrade
Other Financing Activities	3.73	-7.88	-	-0.01	-3	Upgrade
Financing Cash Flow	3.73	-7.88	-	-0.01	-3	Upgrade
Net Cash Flow	-0.04	-23.76	14.52	1	8.08	Upgrade
Free Cash Flow	-6.51	-15.89	14.52	1.01	11.08	Upgrade
Free Cash Flow Growth	-	-	1344.28%	-90.93%	-1.12%	Upgrade
Free Cash Flow Margin	-11.46%	-41.83%	39.91%	2.69%	44.65%	Upgrade
Free Cash Flow Per Share	-0.09	-0.16	0.14	0.01	0.11	Upgrade
Cash Income Tax Paid	5.39	4.33	3	1.76	3.19	Upgrade

Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.